127
Table 29. Medical Cancer Therapy Associated With Increased
Risk of AF (>1%)
Cancer Therapy
Frequency Reported
in Clinical Trials and
Observational Studies Comments
Tyrosine kinase
inhibitors (TKIs)
Ibrutinib (Bruton's
kinase inhibitor
[BTKi])
×
†
×
†
†
Reported AF rates with
ibrutinib have varied across
trials (4%–18%), partly
related to varying duration of
follow-up and patient factors.
Second-generation BTKis
have more selective Bruton's
tyrosine kinase (BTK) activity
and are associated with a lower
incidence of AF than ibrutinib
Based on US FDA adverse
event reporting system
×
Acalbrutinib (2nd-
generation BTKi)
×
Zanubrutinib (2nd-
generation BTKi)
×
Ponatinib (BCR-
ABL TKI) and other
TKIs (eg, trametinib,
osimertinib, nilotinib,
ribociclib)
×
VEGF inhibitor
Sorafenib in
combination with 5FU
BRAF inhibitor
Vemurafenib
Chimeric antigen
receptor (CAR) T-cell
therapy
Tisagenlecleucel
Axicabtagene ciloleucel
×
Monoclonal antibodies
Rituximab
×
Table developed by Atrial Fibrillation Guideline Writing Committee. Data extracted from
Buza V et al. Circ Arrhythm Electrophysiol. 2017;10:e005443, Fradley MG et al. Circulation.
2021;144:e41-e55.
(cont'd)
